CategoryDMT trials

Bexarotene for remyelination, the full article is now available

This study is now finally published. The initial findings were presented virtually at the last ECTRIMS and although the study was negative (i.e. the primary outcome was not met) it is still interesting to read the whole caboodle in the final article. The road to remyelination has been a tough one, and this one in particular is underpinned by at least a decade of basic science preceding it...

Olympics Over…Paralympics Begins ProfK gets Gold for Marathon, after crossing the line…the starting line……..First person in!

Every week we get a news letter of Queen Mary in the News….they forget to mention the times when we are on the naughty-list but this week we should celebrate the marthon win for ProfK. He has been running this marathon since about 2012 and has managed to get cladribine trial (ChariotMS) over the line in 2021 and the first person has been recruited to the trial………..only...

SIZOMUS randomized clinical trial is on the roll

SIZOMUS anti-plasma cell RCT I’m happy to notify that SIZOMUS (Safety of IxaZOmib targeting plasma cells in Multiple Sclerosis) is re-commencing after MHRA approval. This follows a pre-planned interim safety analysis. MHRA stands for Medicines & Healthcare products Regulatory Agency and without their say so this trial would not have been able to proceed. The Medicines and...

ProfK for Number 10

No this is not a call for ProfK to become the next Prime Minister,but I am sure he would have done a better job. However, as German with a knowledge of oral Cladribine what are his Expert Thoughts? You will note there are nine german neurologists….PofK can be the tenth one Stangel M, Becker V, Elias-Hamp B, Havla J, Grothe C, Pul R, Rau D, Richter S, Schmidt S. Oral pulsed therapy of...

A no-brainer?

Barts-MS rose-tinted-odometer: ★★★★★ (aquamarine on a very rainy Friday in London, #00FFBF)  I recently had a patient of mine who has been desperate to be treated with alemtuzumab actually ask if he can change his mind and rather be referred for AHSCT (autologous hematopoietic stem cell transplantation). Why? Because the chances of being put into long term remission, and hence potentially...

Fingolimod vs. Siponimod

Barts-MS rose-tinted-odometer: ★★ (mid-week sepia = #704214) In my post on rebound disease activity in a person with secondary progressive MS switching from fingolimod to siponimod, someone asked whether there is any logic in switching DMTs within the class of S1P modulators. Two or three years ago I would have said no, but now I would say yes. There are well defined and clear differences between...

ChariotMS – we’re rolling !

And we’re off… Almost exactly three years after submitting our outline application to the NIHR-EME, the first site initiation visit of ChariotMS will take place TODAY at my home site, The Royal London Hospital. We are expecting the first of 200 people with advanced MS to enrol in June. And as the remainder of 20 sites across all nations of the UK will open over the next three months...

Translate

Categories

Recent Posts

Recent Comments

Archives